Skip to main content
. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5

Figure 2.

Figure 2

Characterization of the patients’ IFN-DCs used in the clinical trial. IFN-DCs were checked for viability and recovery and capability of antigen uptake(a), and characterized for typical differentiation and activation markers (b) as well as class I-II and costimulation molecules (c).